For patients with ischaemic heart disease, which is part of the recommended pharmacotherapy?

In the management of ischaemic heart disease, aspirin is a cornerstone of pharmacotherapy. It acts as an antiplatelet agent, which helps to prevent the formation of blood clots that can lead to heart attacks and other cardiovascular events. By inhibiting the aggregation of platelets, aspirin effectively reduces the risk of thrombotic complications in patients with existing ischaemic heart disease.

The use of aspirin is supported by numerous clinical guidelines, and the evidence shows that it significantly decreases morbidity and mortality associated with coronary artery disease. Aspirin is particularly beneficial for patients who have already suffered an acute coronary syndrome or possess risk factors for cardiovascular events. Its long-term use in secondary prevention is widely endorsed in the medical community.

In contrast, the other options do not have a role in the routine management of ischaemic heart disease. Antibiotics are used to treat infections, antihistamines are used for allergic reactions, and analgesics may provide relief from pain but do not address the underlying pathophysiology of ischaemic heart disease. Hence, aspirin stands out as the appropriate choice for pharmacotherapy in this context.